Ultragenyx Bundle
Who owns Ultragenyx today?
A pivotal 2014 Nasdaq IPO transformed Ultragenyx from venture control to a public company, shifting governance and capital for its rare-disease pipeline. Founded in 2010 in Novato, CA, the company focuses on enzyme replacement, gene therapy, and small molecules for ultra-rare disorders.
As of 2024–2025, ownership is dominated by institutional investors within a one-share–one-vote structure, with founders and early backers holding smaller, disclosed stakes; ownership shifted through IPOs, follow-on financings, and partnerships. See Ultragenyx Porter's Five Forces Analysis for strategic context.
Who Founded Ultragenyx ?
Founders and early ownership of Ultragenyx centered on Emil D. Kakkis, M.D., Ph.D., who launched the company in 2010 with a focus on rare-disease enzyme therapies; initial common equity was concentrated with Dr. Kakkis and an employee equity pool while Series A preferred shares went to venture investors.
Founder leadership
Emil D. Kakkis served as founder and chief scientific leader, preserving founder-led scientific control during early company-building.
Initial equity allocation
Common shares at inception were allocated primarily to the founder and an equity incentive pool for employees and management.
Series A investors
Early preferred stock was issued to life-sciences venture investors in Series A and follow-on rounds prior to the 2014 IPO.
Vesting and incentives
Management and employee grants used multi-year vesting to align long-term incentives and attract rare-disease talent.
Standard investor protections
Early financings included protective provisions for preferred stock, ROFR and co-sale rights on founder shares, plus drag/tag provisions.
No public disputes
No material founder ownership disputes were disclosed in SEC filings; ownership shifts were driven by financing and option pool expansion.
Early ownership details such as precise founder percentage were not publicly disclosed in SEC filings; public filings and proxy statements post-IPO (2014) and subsequent 2024–2025 SEC reports remain the authoritative sources for Ultragenyx ownership breakdowns.
Key points on early ownership
Founders, investors and governance features that shaped Ultragenyx's early equity structure.
- Founder-led scientific control with Emil D. Kakkis as the primary founder and executive leader
- Series A and later venture rounds held by life-sciences institutional investors who received preferred shares
- Employee option pool expanded pre-IPO to recruit experienced rare-disease talent
- No public record of founder ownership disputes; transfers governed by financing terms and investor rights
For detailed historical context and strategic implications of Ultragenyx ownership and investor composition, see the article Growth Strategy of Ultragenyx and consult the company's Form S-1 (2014) and later 10-K/DEF 14A filings for up-to-date Ultragenyx ownership, Ultragenyx shareholders, Ultragenyx institutional investors and insider ownership percentages.
Ultragenyx SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Ultragenyx ’s Ownership Changed Over Time?
Key financing milestones — private preferred rounds (2010–2013), the 2014 IPO, multiple follow-on offerings (2015–2020), and post‑2020 equity and convertible financings — reshaped Ultragenyx ownership from founder‑led control toward institutional and passive investor dominance, with founders and insiders holding a low single‑digit stake by 2024–2025.
| Period | Ownership Dynamics | Notable Effects |
|---|---|---|
| 2010–2013 | Preferred rounds, expanded option pool | Investor control via preferred shares; option dilution as pipeline scaled |
| 2014 IPO | Priced at $21 per share; ~$126M gross on ~6.1M shares | Preferred converted to common; institutional free float expanded rapidly |
| 2015–2020 | Follow‑on offerings and ATM issuances | Insider dilution; index inclusion attracted passive funds; supported Crysvita, Mepsevii, Dojolvi commercialization |
| 2021–2025 | Additional equity and convertible financings | Ownership concentrated with large institutions and passive index funds; founders low single‑digit ownership by 2024–2025 |
By 2024–2025 Ultragenyx shareholders are led by major U.S. asset managers; 13F and proxy data show BlackRock and Vanguard among top holders with high‑single to low‑teens percentage ranges each, followed by Wellington, Capital Group, State Street, and T. Rowe Price, while founders and executives retain low‑single‑digit stakes mostly via vested and unvested awards.
Ownership summary: who owns Ultragenyx
Institutional and passive investors now dominate Ultragenyx ownership, reducing founder voting power and increasing focus on governance and pay‑for‑performance alignment.
- Top holders: BlackRock, Vanguard (each often in high‑single to low‑teens % range)
- Other major institutional investors: Wellington, Capital Group, State Street, T. Rowe Price
- Founder/insider ownership: low single‑digit percentage by 2024–2025
- Regulatory filings (13F, proxy) and SEC disclosures detail current beneficial ownership and voting power
For further reading on strategic implications of this ownership evolution see Marketing Strategy of Ultragenyx .
Ultragenyx PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Ultragenyx ’s Board?
The current Ultragenyx board of directors combines the CEO-founder with independent industry veterans and financial experts, reflecting a commercial-stage biopharma governance profile. Independent directors chair audit, compensation, and nominating/governance committees, and voting power follows a one-share-one-vote structure.
| Director | Role | Committee Chairs / Notes |
|---|---|---|
| Founder & CEO | Executive Director | Management leadership; typical executive equity holdings |
| Independent Biotech Veteran | Independent Director | Chair, Nominating & Governance |
| Independent Financial Expert | Independent Director | Chair, Audit Committee |
| Independent Compensation Expert | Independent Director | Chair, Compensation Committee |
Ultragenyx operates a single class of common stock with no disclosed dual-class or super-voting shares, so Ultragenyx ownership and voting power mirror economic stakes; no golden shares or special control provisions are reported. Institutional investors exert influence through proxy votes, say-on-pay and director elections rather than formal board seats, and recent shareholder engagement has focused on executive compensation alignment, clinical risk oversight, and capital allocation discipline.
Key governance facts
Voting power equals economic ownership under a one-share-one-vote model; institutional investors are influential but not controlling.
- No dual-class or super-voting founder shares reported
- Independent directors chair audit, compensation, nominating/governance
- No material proxy contests or activist campaigns disclosed recently
- Shareholder proposals centered on compensation, clinical oversight, capital allocation
For context on corporate mission and values related to governance and leadership, see Mission, Vision & Core Values of Ultragenyx . Latest SEC filings (Form 10-K, proxy statements) and 2024–2025 beneficial ownership reports list top institutional holders and insider equity; top 10 institutional shareholders typically include major mutual funds and ETFs representing combined institutional ownership often exceeding 60% in similar biotech peers, while insider ownership percentages for founders/executives commonly range in public filings between 1% and 10% depending on dilution and option exercise.
Ultragenyx Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Ultragenyx ’s Ownership Landscape?
Since 2021 Ultragenyx ownership has shifted toward larger passive index funds and increased institutional stakes as the company advanced late-stage gene-therapy assets and scaled Crysvita revenue; insider holdings remain diluted from prior equity raises while the company retains a one-share-one-vote public structure.
| Period | Trend | Impact |
|---|---|---|
| 2021–2022 | Equity financings, at‑the‑market offerings, convertibles | Broadened float; founder/insider percentage declined |
| 2023–2024 | Rising passive/index ownership; crossover investor entry | Greater institutional concentration without control shifts |
| 2024–2025 | Incremental accumulation tied to pivotal readouts | Analysts expect further institutional buying if catalysts succeed |
Share repurchases were limited as capital allocation prioritized R&D and commercialization; management emphasized financing flexibility over structural governance changes such as dual‑class stock or privatization.
Ownership composition
Institutions and mutual funds hold the bulk of shares; retail and insiders constitute a smaller percentage after multiple financing events.
Voting structure
The company maintains a one‑share‑one‑vote format consistent with large public biotech governance norms and no controlling shareholder as of 2025 filings.
Capital strategy
Financings via ATM programs and standard convertibles extended runway; limited buybacks kept cash directed to late‑stage trials and Crysvita commercialization.
Market dynamics
Sector trends—index ownership growth, crossover activity pre‑data, and episodic volatility around catalysts—have materially shaped Ultragenyx shareholders and trading patterns.
For a detailed competitive context and additional shareholder‑level references see Competitors Landscape of Ultragenyx
Ultragenyx Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Ultragenyx Company?
- What is Competitive Landscape of Ultragenyx Company?
- What is Growth Strategy and Future Prospects of Ultragenyx Company?
- How Does Ultragenyx Company Work?
- What is Sales and Marketing Strategy of Ultragenyx Company?
- What are Mission Vision & Core Values of Ultragenyx Company?
- What is Customer Demographics and Target Market of Ultragenyx Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.